Drugs that contain Pancrelipase (amylase;lipase;protease)
1. Creon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9198871 | ABBVIE | Delayed release pancreatin compositions |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2014 |
| M(M-93) | Jul 29, 2019 |
| New Indication(I-625) | Apr 30, 2013 |
NCE-1 date: 30 April, 2013
Market Authorisation Date: 30 April, 2009
Treatment: Treatment of exocrine pancreatic insufficiency
Dosage: CAPSULE, DELAYED RELEASE;ORAL
CREON family patents
2. Pancreaze patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562978 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562981 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562980 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562979 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8221747 | VIVUS INC | Stable pancreatic enzyme compositions |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2015 |
NCE-1 date: 12 April, 2014
Market Authorisation Date: 07 March, 2014
Treatment: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Dosage: CAPSULE, DELAYED RELEASE;ORAL
PANCREAZE family patents
3. Zenpep patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8221747 | APTALIS PHARMA US | Stable pancreatic enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8246950 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562978 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US7658918 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562980 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562979 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562981 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2014 |
NCE-1 date: 27 August, 2013
Market Authorisation Date: 25 March, 2014
Treatment: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Dosage: CAPSULE, DELAYED RELEASE;ORAL
ZENPEP family patents
4. Zenpep patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562978 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562980 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562981 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8221747 | ZENPEP | Stable pancreatic enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562979 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2014 |
NCE-1 date: 27 August, 2013
Market Authorisation Date: 25 March, 2014
Treatment: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Dosage: CAPSULE, DELAYED RELEASE;ORAL
ZENPEP family patents